AbbVie Inc (ABBV)vsGuardian Pharmacy Services, Inc. (GRDN)
ABBV
AbbVie Inc
$227.23
-2.69%
HEALTHCARE · Cap: $380.57B
GRDN
Guardian Pharmacy Services, Inc.
$40.48
-0.78%
HEALTHCARE · Cap: $2.73B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 4215% more annual revenue ($62.82B vs $1.46B). ABBV leads profitability with a 5.8% profit margin vs 3.6%. GRDN trades at a lower P/E of 51.3x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
GRDN
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for GRDN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Safe zone — low bankruptcy risk
Every $100 of equity generates 24 in profit
Conservative balance sheet, low leverage
Earnings expanding 39.0% YoY
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Trading at 11.6x book value
2.2% revenue growth
3.6% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : GRDN
The strongest argument for GRDN centers on Altman Z-Score, Return on Equity, Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : GRDN
The primary concerns for GRDN are Price/Book, Revenue Growth, Profit Margin. A P/E of 51.3x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 50/100) and 12.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Guardian Pharmacy Services, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Guardian Pharmacy Services, Inc. is a leading provider of specialized pharmacy solutions focused on the long-term care sector, serving assisted living and skilled nursing facilities. The company is recognized for its commitment to personalized medication management, high standards of quality and compliance, and superior customer service. By utilizing advanced technology and deep pharmaceutical expertise, Guardian not only improves patient outcomes but also streamlines operations for healthcare partners. With a substantial operational presence in multiple states, Guardian is well-equipped to address the growing demand for tailored pharmacy services in a rapidly evolving healthcare environment.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?